Objective:To investigate the relationship between the level of serum B-type natriuretic peptide(BNP) and right ventricular infarction in patient s with acute inferior myocardial infarction(AIMI).Method:The serum BNP l...
详细信息
Objective:To investigate the relationship between the level of serum B-type natriuretic peptide(BNP) and right ventricular infarction in patient s with acute inferior myocardial infarction(AIMI).Method:The serum BNP level was measured in 213 consecutive patient s with AIMI who were admitted in the coronary care unit(CCU) and in the normal control with 98 cases from October 2006 to May *** patients were divided into five groups in accordance with the coronary angiographic findings and electrocardiogram(ECG):Acute inferior myocardial infarction group;acute inferior myocardial infarction and right ventricular infarction group;control group;left anterior circumflex(LXC) group;proximal,middle and distal segment of right coronary artery(RCA)*** patient s were performed directly percutaneous coronary intervention(PCI) within 24 hours after the onset of *** incidence of major adverse cardiac events(MACE),including arrhythmia, heart failure,cardiac shock and mortality,had been observed during hospital,30 days and 3 ***:BNP level in the acute inferior myocardial infarction and right ventricular infarction group was significantly higher than that in acute inferior myocardial infarction group(P<0101).The level in the proximal2mid segment of RCA group was higher than that in the LXC group(P<0101).Additionally,logistic regression analysis showed that the level of BNP was an independent predictor of MACE in the 30 days and 3 months in acute inferior myocardial infarction patient s (r=0.701 0,95%CI<0.01 - 0.615,P<0101).Conclusion:We demonstrated the level of BNP in patients with acute inferior myocardial infarction or/ and right ventricular infarction,and BNP could be a good predictor for patients with acute inferior myocardial infarction and right ventricular infarction.
Background Trastuzumab is used widely for the treatment of early and advanced breast ***,concerns have arisen regarding its cardiac *** did a systematic review and meta-analysis of published randomized controlled tria...
详细信息
Background Trastuzumab is used widely for the treatment of early and advanced breast ***,concerns have arisen regarding its cardiac *** did a systematic review and meta-analysis of published randomized controlled trials(RCTs) to assess the overall risk of cardiac dysfunction associated with trastuzumab treatment. Methods We searched PubMed and Web of Science(January 1966 to July 2009) and American Society of Clinical Oncology conferences held(January 2000 to July 2009) for relevant articles and *** incidence rates,relative risks(RRs),and 95%confident intervals(CIs) were calculated using a fixed-effects or random-effects model. Results 11,892 patients from 10 RCTs were included for *** incidences of LVEF decrease and congested heart failure(CHF) were 7.5%(95%CI 4.2-13.1) and 1.9%(95%CI 1.0-3.8) among patients receiving *** significantly increased the risk of LVEF decrease(RR=1.75,95%CI,1.16-2.64;p=0.007).In addition,it significantly increased the risk of CHF(RR=4.23,95%CI, 2.76-6.48;p<0.001).The increased risk of CHF was observed in patients with early stage(RR=4.39,95%CI,2.54-7.60;p<0.001) as well as metastatic disease(RR=4.94, 95%CI,2.0-12.19;p=0.005).Furthermore,trastuzumab significantly increased the risk of CHF(RR=4.27;95%CI:2.75-6.61,p<0.001) in patients receiving anthracycline-based chemotherapy,but not in patients receiving non-anthracycline chemotherapy(RR= 2.42;95%CI:0.36-16.19,p=0.36). Conclusion The addition of trastuzumab to anthracycline-based chemotherapy may significantly increase the risk of cardiac dysfunction in breast cancer *** studies are recommended for non-anthracycline chemotherapy.
Background—In China,the occurrence rule,mechanisms and prevention measures of diseases under extreme weather are few reported,and which only focused on pathophysiological manifestation rather than molecular mechanism...
详细信息
Background—In China,the occurrence rule,mechanisms and prevention measures of diseases under extreme weather are few reported,and which only focused on pathophysiological manifestation rather than molecular mechanism *** further study in this work will be carried out from molecular cytological *** study explored the effect of hyperthermia on ventricular cardiomyocytes and the participative roles of classic MAPK—ERK5 pathways on hyperthermia induced cardiomyocytes damage. Materials and methods—Neonatal rat ventricular cardiac myocytes(NRVM) were isolated from the hearts of 1- to 3-day-old Sprague Dawley *** were exposed to hyperthermia(42℃,60 min) *** degree of cell damage was observed at 0,4,8,12,16,and 24 hours after *** effects of hyperthermia on myocardial cells were probed by evaluating lactate dehydrogenase(LDH) release, cells beating rate and rhythm and viability(assessed by MTS assay).Apoptosis was detected using an annexin V-FITC/propidium iodide(PI) staining binding assay. Using western blot semi-quantitating Bim and extracellular signal-related kinase (ERK5) / phosphorylated extracellular signal-related kinase(p-ERK).Using PD98059 as inhibitor of MAPK pathways,semi-quantitating Bim by western blot. RESULTS—(1) the beating rate of myocardial cells was slightly decreased immediately after temperature recovery,gradually decreased with time prolonged,and the cell viability was decreased(P<0.05);the activity of lactate dehydrogenase was increased(P<0.05).(2) Based on western blot analysis,the elevation of Bim protein expression occurred at recovery time(8h) and peaked at 12h then went down slowly at 24h after hyperthermia(P<0.05);ERK5 pathway responding to hyperthermia treatment(P<0.05).(3) Levels of Bim slightly decreased at PD98059 group compared with hyperthermia group(P<0.05) CONCLUSION—Hyperthermia induces myocardial cells damage with apoptosis as main ***5 participated the injure process of *** play
暂无评论